Readoutin 45d
IDEAYA Biosciences — IDE196
Phase 3 primary completion: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Metastatic Uveal Melanoma
Readoutin 45d
Phase 3 primary completion: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.